Market Research Logo

Uveal Melanoma - Pipeline Review, H1 2018

Uveal Melanoma - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H1 2018, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 12, 10, 1 and 7 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 1 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Uveal Melanoma - Overview
Uveal Melanoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Uveal Melanoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Uveal Melanoma - Companies Involved in Therapeutics Development
Aeglea BioTherapeutics Inc
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
Celldex Therapeutics Inc
Cleveland BioLabs Inc
Delcath Systems Inc
Eli Lilly and Co
Iconic Therapeutics Inc
Immunocore Ltd
Iovance Biotherapeutics Inc
Novartis AG
PEP-Therapy SAS
Pfizer Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Tesaro Inc
Viralytics Ltd
Uveal Melanoma - Drug Profiles
AU-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPX-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cavatak - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Metastatic Uveal Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target GP100 for Melanoma and Non Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emibetuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galunisertib monohydrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glembatumumab vedotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HDM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HPH-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HPH-211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICON-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMCgp-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LXS-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melphalan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAV-2729 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niraparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegargiminase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegzilarginase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-2853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sotrastaurin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sunitinib malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulixertinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Uveal Melanoma - Dormant Projects
Uveal Melanoma - Discontinued Products
Uveal Melanoma - Product Development Milestones
Featured News & Press Releases
Jan 09, 2018: Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
Dec 11, 2017: Immunocores IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
Dec 05, 2017: Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology
Nov 13, 2017: Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate
Oct 31, 2017: Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Jun 05, 2017: Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting
Jun 01, 2017: Immunocore Highlights IMCgp100 clinical data in Uveal Melanoma at ASCO 2017 Annual Meeting
Nov 09, 2016: Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress
Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016
Mar 30, 2016: Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
Jan 25, 2016: Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
Sep 09, 2015: Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme
Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma
May 22, 2015: Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Uveal Melanoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Uveal Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
Uveal Melanoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2018
Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H1 2018
Uveal Melanoma - Pipeline by Delcath Systems Inc, H1 2018
Uveal Melanoma - Pipeline by Eli Lilly and Co, H1 2018
Uveal Melanoma - Pipeline by Iconic Therapeutics Inc, H1 2018
Uveal Melanoma - Pipeline by Immunocore Ltd, H1 2018
Uveal Melanoma - Pipeline by Iovance Biotherapeutics Inc, H1 2018
Uveal Melanoma - Pipeline by Novartis AG, H1 2018
Uveal Melanoma - Pipeline by PEP-Therapy SAS, H1 2018
Uveal Melanoma - Pipeline by Pfizer Inc, H1 2018
Uveal Melanoma - Pipeline by Plexxikon Inc, H1 2018
Uveal Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2018
Uveal Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2018
Uveal Melanoma - Pipeline by Tesaro Inc, H1 2018
Uveal Melanoma - Pipeline by Viralytics Ltd, H1 2018
Uveal Melanoma - Dormant Projects, H1 2018
Uveal Melanoma - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Uveal Melanoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report